BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 10524570)

  • 1. Degradation of extracellular matrix by metastatic follicular thyroid carcinoma cell lines: role of the plasmin activation system.
    Smit JW; van der Pluijm G; Romijn HA; Löwik CW; Morreau H; Goslings BM
    Thyroid; 1999 Sep; 9(9):913-9. PubMed ID: 10524570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial effects of retinoic acid on extracellular matrix degradation and attachment behaviour in follicular thyroid carcinoma cell lines.
    Havekes B; Schröder van der Elst JP; van der Pluijm G; Goslings BM; Romijn JA; Smit JW
    J Endocrinol; 2000 Nov; 167(2):229-38. PubMed ID: 11054636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of IL-1alpha on the expression of matrix metalloproteinases, plasminogen activators, and their inhibitors in osteoblastic ROS 17/2.8 cells.
    Fujisaki K; Tanabe N; Suzuki N; Mitsui N; Oka H; Ito K; Maeno M
    Life Sci; 2006 Mar; 78(17):1975-82. PubMed ID: 16313928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
    Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
    Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of matrix metalloproteinases and their specific inhibitors in normal and different human thyroid tumor cell lines.
    Baldini E; Toller M; Graziano FM; Russo FP; Pepe M; Biordi L; Marchioni E; Curcio F; Ulisse S; Ambesi-Impiombato FS; D'Armiento M
    Thyroid; 2004 Nov; 14(11):881-8. PubMed ID: 15671765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of intrafollicular indomethacin injection on gonadotropin surge-induced expression of select extracellular matrix degrading enzymes and their inhibitors in bovine preovulatory follicles.
    Li Q; Jimenez-Krassel F; Kobayashi Y; Ireland JJ; Smith GW
    Reproduction; 2006 Mar; 131(3):533-43. PubMed ID: 16514196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extracellular matrix production and degradation by adenoid cystic carcinoma cells: participation of plasminogen activator and its inhibitor in matrix degradation.
    Shirasuna K; Saka M; Hayashido Y; Yoshioka H; Sugiura T; Matsuya T
    Cancer Res; 1993 Jan; 53(1):147-52. PubMed ID: 8380125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
    Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors.
    Guda K; Claffey KP; Dong M; Nambiar PR; Rosenberg DW
    Mol Carcinog; 2003 May; 37(1):51-9. PubMed ID: 12720300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
    Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
    Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of integrins in the attachment of metastatic follicular thyroid carcinoma cell lines to bone.
    Smit JW; van der Pluijm G; Vloedgraven HJ; Löwik CW; Goslings BM
    Thyroid; 1998 Jan; 8(1):29-36. PubMed ID: 9492150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of CLAUDIN-1 on follicular thyroid carcinoma aggressiveness.
    Zwanziger D; Badziong J; Ting S; Moeller LC; Schmid KW; Siebolts U; Wickenhauser C; Dralle H; Fuehrer D
    Endocr Relat Cancer; 2015 Oct; 22(5):819-30. PubMed ID: 26219679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The plasminogen-activating system in hepatic stellate cells.
    Leyland H; Gentry J; Arthur MJ; Benyon RC
    Hepatology; 1996 Nov; 24(5):1172-8. PubMed ID: 8903394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: correlation with metastatic behavior in vivo.
    Quax PH; de Bart AC; Schalken JA; Verheijen JH
    Prostate; 1997 Aug; 32(3):196-204. PubMed ID: 9254899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of various matrix proteases and Ets family transcriptional factors in ovarian cancer cell lines: correlation to invasive potential.
    Nishikawa A; Iwasaki M; Akutagawa N; Manase K; Yamashita S; Endo T; Kudo R
    Gynecol Oncol; 2000 Nov; 79(2):256-63. PubMed ID: 11063654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
    Quax PH; van Muijen GN; Weening-Verhoeff EJ; Lund LR; Danø K; Ruiter DJ; Verheijen JH
    J Cell Biol; 1991 Oct; 115(1):191-9. PubMed ID: 1918136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.
    Allan EH; Martin TJ
    J Cell Physiol; 1995 Dec; 165(3):521-9. PubMed ID: 7593231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming growth factor-beta1 inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system.
    Ramont L; Pasco S; Hornebeck W; Maquart FX; Monboisse JC
    Exp Cell Res; 2003 Nov; 291(1):1-10. PubMed ID: 14597403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer.
    Castelló R; Estellés A; Vázquez C; Falcó C; España F; Almenar SM; Fuster C; Aznar J
    Clin Chem; 2002 Aug; 48(8):1288-95. PubMed ID: 12142386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cooperation of urokinase plasminogen activator and matrix metalloproteinases in NK cell invasion.
    al-Atrash G; Kitson RP; Xue Y; Goldfarb RH
    In Vivo; 2000; 14(5):565-70. PubMed ID: 11125540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.